Skip to main content
. 2022 Feb 28;5(2):e220426. doi: 10.1001/jamanetworkopen.2022.0426

Figure 3. Subgroup Analysis of Overall Survival (OS) in the S-1 Plus Oxaliplatin (SOX) Group Compared With the Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) Group.

Figure 3.

Hazard ratios (HRs) for death and P values show no significance of heterogeneity of treatment effect according to the sex, age, Eastern Cooperative Oncology Group (ECOG) status, and primary tumor location.